A detailed history of Bryn Mawr Trust CO transactions in Uni Qure N.V. stock. As of the latest transaction made, Bryn Mawr Trust CO holds 352 shares of QURE stock, worth $6,107. This represents 0.0% of its overall portfolio holdings.

Number of Shares
352
Holding current value
$6,107
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 25, 2024

BUY
$3.78 - $10.12 $1,330 - $3,562
352 New
352 $1,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $811M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Bryn Mawr Trust CO Portfolio

Follow Bryn Mawr Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bryn Mawr Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Bryn Mawr Trust CO with notifications on news.